Shareholders Approve SeraCare Sale to Private Equity Firm | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences shareholders have approved the $82 million sale of the firm to private equity firm Linden Capital Partners, SeraCare announced today.

Under the terms of the deal, originally announced in February, holders of outstanding shares of SeraCare's common stock will receive $4 per share. The deal is expected to close on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A recent study examines how a paper, despite being retracted, can influence its field, Retraction Watch reports.

In Science this week: CRISPR-based approach to identify gene variants, and more.

Stat News profiles the Wellcome Trust's Jeremy Farrar.

France's research minister tells Nature News that he hopes to simplify the research bureaucracy and improve funding.